{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:49:27Z","timestamp":1782485367380,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04997-y","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:05:48Z","timestamp":1767492348000},"page":"2603-2607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists: an emerging hope against nephrolithiasis risk reduction via body weight reduction"],"prefix":"10.1007","volume":"58","author":[{"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"4997_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"2025","unstructured":"Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, Abbas N, Abbasian M, Abd ElHafeez S, Abdel-Rahman WM, Abd-Elsalam S (2025) Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405:813\u2013838","journal-title":"Lancet"},{"key":"4997_CR2","first-page":"63","volume":"17","author":"E Emami","year":"2023","unstructured":"Emami E, Heidari-Soureshjani S, Oroojeni Mohammadjavad A, Sherwin CM (2023) Obesity and the risk of developing kidney stones: a systematic review and meta-analysis. Iran J Kidney Dis 17:63\u201372","journal-title":"Iran J Kidney Dis"},{"key":"4997_CR3","first-page":"17","volume":"22","author":"W Poore","year":"2020","unstructured":"Poore W, Boyd CJ, Singh NP, Wood K, Gower B, Assimos DG (2020) Obesity and its impact on kidney stone formation. Rev Urol 22:17\u201323","journal-title":"Rev Urol"},{"key":"4997_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrurol.2015.67","volume":"12","author":"S Tarplin","year":"2015","unstructured":"Tarplin S, Ganesan V, Monga M (2015) Stone formation and management after bariatric surgery. Nat Rev Urol 12:263\u2013270","journal-title":"Nat Rev Urol"},{"key":"4997_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.soard.2016.04.004","volume":"12","author":"S Upala","year":"2016","unstructured":"Upala S, Jaruvongvanich V, Sanguankeo A (2016) Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. Surg Obes Relat Dis 12:1513\u20131521","journal-title":"Surg Obes Relat Dis"},{"key":"4997_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3892\/etm.2021.10601","volume":"22","author":"MC Tilinca","year":"2021","unstructured":"Tilinca MC, Tiuca RA, Niculas C, Varga A, Tilea I (2021) Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp Ther Med 22:1167","journal-title":"Exp Ther Med"},{"key":"4997_CR7","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Ryd\u00e9n L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM (2024) Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 30:2058\u20132066","journal-title":"Nat Med"},{"key":"4997_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1186\/s12889-024-19229-8","volume":"24","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zheng H, Yin H, Yin D, Wang H, Wang Y, Tang Q, Gu S (2024) Changes in metabolic overweight phenotypes over time and risk of nephrolithiasis: a cohort study. BMC Public Health 24:1898","journal-title":"BMC Public Health"},{"key":"4997_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z (2025) Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med 31:951\u2013962","journal-title":"Nat Med"},{"key":"4997_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003225.05","volume":"209","author":"K Zhao","year":"2023","unstructured":"Zhao K, Shkolnik B, Lu J, Miller J, Schulsinger D (2023) MP10-05 lithoprotective effect of glp-1 agonists in diabetic stone formers. J Urol 209:e115","journal-title":"J Urol"},{"key":"4997_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001109820.51058.5a.36","volume":"213","author":"S Thiagarajan","year":"2025","unstructured":"Thiagarajan S, Di Scipio S, Wolde K, Sadiq A (2025) IP06-36 characterizing kidney stone episodes by glp-1ra medication in GLP-1RA users. J Urol 213:e328","journal-title":"J Urol"},{"key":"4997_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.34067\/KID.0000000580","volume":"5","author":"K Feghali","year":"2024","unstructured":"Feghali K, Li X, Maalouf NM (2024) Changes in 24-hour urine chemistry in patients with nephrolithiasis during weight loss with glucagon-like peptide 1-based therapies. Kidney360 5:1706\u20131712","journal-title":"Kidney360"},{"key":"4997_CR13","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1210\/jc.2003-031403","volume":"89","author":"JP Gutzwiller","year":"2004","unstructured":"Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055\u20133061","journal-title":"J Clin Endocrinol Metab"},{"key":"4997_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/dom.12601","volume":"18","author":"MH Muskiet","year":"2016","unstructured":"Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, van Raalte DH (2016) Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab 18:178\u2013185","journal-title":"Diabetes Obes Metab"},{"key":"4997_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1053\/j.ajkd.2006.09.004","volume":"48","author":"EN Taylor","year":"2006","unstructured":"Taylor EN, Curhan GC (2006) Body size and 24-hour urine composition. Am J Kidney Dis 48:905\u2013915","journal-title":"Am J Kidney Dis"},{"key":"4997_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00345-022-04268-w","volume":"41","author":"R Siener","year":"2023","unstructured":"Siener R, Metzner C (2023) Dietary weight loss strategies for kidney stone patients. World J Urol 41:1221\u20131228","journal-title":"World J Urol"},{"key":"4997_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112088","volume":"222","author":"JA Yeh","year":"2025","unstructured":"Yeh JA, Liu YC, Huang AH, Peng CC, Loh CH, Munir KM, Huang HK (2025) SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: a cohort study and meta-analysis. Diabetes Res Clin Pract 222:112088","journal-title":"Diabetes Res Clin Pract"},{"key":"4997_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamainternmed.2023.7660","volume":"184","author":"JM Paik","year":"2024","unstructured":"Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E (2024) Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. JAMA Intern Med 184:265\u2013274","journal-title":"JAMA Intern Med"},{"key":"4997_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13196017","author":"\u017d Dika","year":"2024","unstructured":"Dika \u017d, \u017divko M, Kljaji\u0107 M, Jelakovi\u0107 B (2024) SGLT2 inhibitors and their effect on urolithiasis: current evidence and future directions. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13196017","journal-title":"J Clin Med"},{"key":"4997_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.34067\/KID.0000000728","volume":"6","author":"JA Schaub","year":"2025","unstructured":"Schaub JA, Oerline MK, Crivelli JJ, Maalouf NM, Best SL, Asplin JR, Hollingsworth JM, Shahinian V, Hsi RS (2025) The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on 24-hour urine parameters: a retrospective cohort study. Kidney360 6:835\u2013847","journal-title":"Kidney360"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04997-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:19:10Z","timestamp":1782483550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04997-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4997"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04997-y","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}